ଓମାଲିଜୁମାବ

ଓମାଲିଜୁମାବ
	ଫାଇଲ:Omalizumab syringe (DermNet NZ xolair-syringe-01).jpg Omalizumab syringe
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IgE Fc region
Clinical data
Pronunciation	oh-ma-liz'-oom-ab
Trade names	Xolair
AHFS/Drugs.com	monograph
MedlinePlus	a603031
data	EU EMA: yes; US DailyMed: Omalizumab;
Pregnancy; category	AU: B1 ; ;
Routes of; administration	Subcutaneous
Legal status
Legal status	AU: S4 (Prescription only) ; CA: Rx-only; Schedule D ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Elimination half-life	26 days
Chemical and physical data
Formula	C6450H9916N1714O2023S38
Molar mass	୧,୪୫,୦୫୮.୫୩ g·mol−1
(verify)

ଓମାଲିଜୁମାବ, ଏକ ବେପାର ନାମ ଜୋଲେୟାର/ Xolair) ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆଜ୍‌ମା, ନାକ ପଲିପ୍ ଏବଂ ହାଇଭ୍‌ସର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ^[୭] ଆଲର୍ଜି ଥାଇ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ଯଥେଷ୍ଟ ନ ହେଲେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଏହା ଇଞ୍ଜେକସନଦ୍ୱାରା ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଇଞ୍ଜେକସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା, ଗଲୁ ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲକ୍‌ସିସ, କର୍କଟ ଏବଂ ହୃଦରୋଗ ହୋଇପାରେ। ^[୭] ପରୀକ୍ଷା ମୂଳକ ଭାବରେ ଅଳ୍ପ ସଂଖ୍ୟକ ଗର୍ଭବତୀ ମହିଳାଙ୍କ ବ୍ୟବହାର ପରେ ଶିଶୁର କୌଣସି କ୍ଷତି ହେବାର ପ୍ରମାଣ ମିଳି ନାହିଁ ।^[୮] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଇମ୍ୟୁନୋଗ୍ଲୋବୁଲିନ ଇ (IgE) ସାଥିରେ ବାନ୍ଧି ହୋଇ ନିଷ୍କ୍ରିୟ କରିଥାଏ ।^[୪]

ଓମାଲିଜୁମାବ ୨୦୦୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୦୫ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୭] ^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ମସିହା ସୁଦ୍ଧା ଗୋଟିଏ ୧୫୦ ମିଗ୍ରା ପିଛା ପ୍ରାୟ ୨୬୦ ପାଉଣ୍ଡ ହୋଇଥିଲା ।^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧,୨୦୦ ଡଲାର ଅଟେ ।^[୧୦]

ଆଧାର

↑ "Archive copy" (PDF). Archived (PDF) from the original on 2021-06-13. Retrieved 2021-07-15.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "Archive copy" (PDF). Archived (PDF) from the original on 2021-08-28. Retrieved 2021-07-15.{{cite web}}: CS1 maint: archived copy as title (link)
↑ "Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines". Novartis (Press release). 28 August 2014. Archived from the original on 13 June 2021. Retrieved 12 June 2021 – via PR Newswire.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Xolair EPAR". European Medicines Agency (EMA). Archived from the original on 13 June 2021. Retrieved 12 June 2021.
↑ "Xolair 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 18 August 2020. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
↑ "Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution". DailyMed. 11 May 2020. Archived from the original on 28 November 2020. Retrieved 6 December 2020.
↑ ^୭.୦ ^୭.୧ ^୭.୨ "Omalizumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 January 2020. Retrieved 8 November 2021.
↑ "Omalizumab (Xolair) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 December 2020. Retrieved 8 November 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 285. ISBN 978-0857114105.
↑ "Xolair Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 8 November 2021.

[Xolair_AU_PI-1] "Archive copy" (PDF). Archived (PDF) from the original on 2021-06-13. Retrieved 2021-07-15.{{cite web}}: CS1 maint: archived copy as title (link)

[2] "Archive copy" (PDF). Archived (PDF) from the original on 2021-08-28. Retrieved 2021-07-15.{{cite web}}: CS1 maint: archived copy as title (link)

[3] "Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines". Novartis (Press release). 28 August 2014. Archived from the original on 13 June 2021. Retrieved 12 June 2021 – via PR Newswire.

[EPAR2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Xolair EPAR". European Medicines Agency (EMA). Archived from the original on 13 June 2021. Retrieved 12 June 2021.

[5] "Xolair 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 18 August 2020. Archived from the original on 13 June 2021. Retrieved 12 June 2021.

[Xolair_FDA_label-6] "Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution". DailyMed. 11 May 2020. Archived from the original on 28 November 2020. Retrieved 6 December 2020.

[AHFS2021-7] ୭.୦ ^୭.୧ ^୭.୨ "Omalizumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 January 2020. Retrieved 8 November 2021.

[8] "Omalizumab (Xolair) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 December 2020. Retrieved 8 November 2021.

[BNF81-9] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 285. ISBN 978-0857114105.

[10] "Xolair Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 8 November 2021.

[୪]

[୭]

[୧]

[୨]

[୩]

[୫]

[୬]

[୮]

[୯]

[୧୦]